How to buy Moderna stock | $348.83

Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. The vaccine has yet to be approved by the FDA, but the company has applied for emergency authorization and the first doses could be distributed this year, the Washington Post reported Nov. 30.
Here’s how to buy Moderna stock.

Moderna’s COVID-19 vaccine

On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.

Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.

Moderna has now applied for emergency-use approval from the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.

In response to Moderna’s November announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.

Moderna vs. Pfizer

Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.

	Moderna	Pfizer
Type of vaccine	Messenger RNA (mRNA)	Messenger RNA (mRNA
Efficacy rate	94.5%	95%
Trial size	30,000 people	43,538 people
Number of doses	2 shots, 28 days apart	2 shots, 21 days apart
Storage	-20°C	-70°C
Production	Up to 20 million doses by the end of 2020	Up to 50 million doses by the end of 2020
Years in business	10	171
Number of manufactured drugs	0	300+

How has coronavirus impacted Moderna's share price?

Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.

Its last close price was $348.83, which is 94.77% up on its pre-crash value of $18.23 and 1,847.68% up on the lowest point reached during the March crash when the shares fell as low as $17.91.

If you had bought $1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $17.00.

Moderna stock price (NASDAQ: MRNA)

Use our graph to track the performance of MRNA stocks over time.

Moderna shares at a glance

• Live prices
• Key figures

Information last updated 2021-07-23.

Open	$330.90
High	$349.41
Low	$325.17
Close	$348.83
Previous close	$323.48
Change	$25.35
Change %	7.8367%
Volume	23,431,397

Information last updated 2021-07-30.

52-week range	$54.21 - $362.00
50-day moving average	$250.12
200-day moving average	$179.85
Wall St. target price	$184.92
PE ratio	231.6622
Dividend yield	N/A (0%)
Earnings per share (TTM)	$1.49

Buy Moderna shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Moderna, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moderna price performance over time

Historical closes compared with the close of $348.83 from 2021-06-04

1 week (2021-07-20)	N/A
1 month (2021-07-01)	48.37%
3 months (2021-04-30)	95.07%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Is Moderna under- or over-valued?

Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Moderna's P/E ratio

Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 232x. In other words, Moderna shares trade at around 232x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Moderna's EBITDA

Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $673.1 million.

The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.

Moderna financials

Revenue TTM	$2.7 billion
Operating margin TTM	23.2%
Gross profit TTM	$-574,877,000
Return on assets TTM	5.37%
Return on equity TTM	21.83%
Profit margin	21.88%
Book value	$9.57
Market capitalisation	$138.8 billion

TTM: trailing 12 months

Shorting Moderna shares

There are currently 12.5 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 13% down from 14.3 million last month.

There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 7.3 million). Moderna's SIR currently stands at 1.71. In other words for every 100,000 Moderna shares traded daily on the market, roughly 1710 shares are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.0399% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna share price volatility

Over the last 12 months, Moderna's shares have ranged in value from as little as $54.21 up to $362. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4749. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moderna overview

Moderna, Inc. , a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co. , Inc. , Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc.

Frequently asked questions

What percentage of Moderna is owned by insiders or institutions?
Currently 9.67% of Moderna shares are held by insiders and 54.474% by institutions. How many people work for Moderna?
Latest data suggests 1,300 work at Moderna. When does the fiscal year end for Moderna?
Moderna's fiscal year ends in December. Where is Moderna based?
Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139 What is Moderna's ISIN number?
Moderna's international securities identification number is: US60770K1079 What is Moderna's CUSIP number?
Moderna's Committee on Uniform Securities Identification Procedures number is: 56804Q201